Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
Marinomed Biotech AG: Court opens restructuring proceedings without self-administration
Marinomed Biotech AG applies for court restructuring proceedings without self-administration
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
Adhoc-Announcement
Lucia Ziegler, MSc
Head of Investor & Public Relations